Global Non-Invasive Cancer Diagnostics Market Professional Survey Report 2019

2 Global Non-Invasive Cancer Diagnostics Quarterly Market Size Analysis

• 2.1 Non-Invasive Cancer Diagnostics Business Impact Assessment - COVID-19
  • 2.1.1 Global Non-Invasive Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Non-Invasive Cancer Diagnostics Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Non-Invasive Cancer Diagnostics Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Non-Invasive Cancer Diagnostics Headquarters and Area Served
• 3.3 Date of Key Players Enter into Non-Invasive Cancer Diagnostics Market
• 3.4 Key Players Non-Invasive Cancer Diagnostics Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Non-Invasive Cancer Diagnostics Segments, By Type

• 4.1 Introduction
  • 1.4.1 CTCs
  • 1.4.2 CTNAS
  • 1.4.3 Exosomes
• 4.2 By Type, Global Non-Invasive Cancer Diagnostics Market Size, 2019-2021

5 Impact of Covid-19 on Non-Invasive Cancer Diagnostics Segments, By Application

• 5.1 Overview
  • 5.5.1 Blood
  • 5.5.2 Urine
  • 5.5.3 Saliva
• 5.2 By Application, Global Non-Invasive Cancer Diagnostics Market Size, 2019-2021
  • 5.2.1 By Application, Global Non-Invasive Cancer Diagnostics Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Gen-Probe Inc
  • 7.1.1 Gen-Probe Inc Business Overview
  • 7.1.2 Gen-Probe Inc Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
  • 7.1.3 Gen-Probe Inc Non-Invasive Cancer Diagnostics Product Introduction
  • 7.1.4 Gen-Probe Inc Response to COVID-19 and Related Developments
• 7.2 Digene Corporation
  • 7.2.1 Digene Corporation Business Overview
  • 7.2.2 Digene Corporation Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
  • 7.2.3 Digene Corporation Non-Invasive Cancer Diagnostics Product Introduction
  • 7.2.4 Digene Corporation Response to COVID-19 and Related Developments
• 7.3 Quest Diagnostics Inc
  • 7.3.1 Quest Diagnostics Inc Business Overview
  • 7.3.2 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
  • 7.3.3 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Product Introduction
  • 7.3.4 Quest Diagnostics Inc Response to COVID-19 and Related Developments
• 7.4 Cancer, Genetics Inc
  • 7.4.1 Cancer, Genetics Inc Business Overview
  • 7.4.2 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
  • 7.4.3 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Product Introduction
  • 7.4.4 Cancer, Genetics Inc Response to COVID-19 and Related Developments
• 7.5 BIOVIEW Inc
  • 7.5.1 BIOVIEW Inc Business Overview
  • 7.5.2 BIOVIEW Inc Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
  • 7.5.3 BIOVIEW Inc Non-Invasive Cancer Diagnostics Product Introduction
  • 7.5.4 BIOVIEW Inc Response to COVID-19 and Related Developments
• 7.6 AVIVA Biosciences Corporation
  • 7.6.1 AVIVA Biosciences Corporation Business Overview
  • 7.6.2 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
  • 7.6.3 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Product Introduction
  • 7.6.4 AVIVA Biosciences Corporation Response to COVID-19 and Related Developments
• 7.7 Laboratory Corporation of America Holdings (LabCorp)
  • 7.7.1 Laboratory Corporation of America Holdings (LabCorp) Business Overview
  • 7.7.2 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
  • 7.7.3 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Product Introduction
  • 7.7.4 Laboratory Corporation of America Holdings (LabCorp) Response to COVID-19 and Related Developments
• 7.8 A&G Pharmaceutical
  • 7.8.1 A&G Pharmaceutical Business Overview
  • 7.8.2 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
  • 7.8.3 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Product Introduction
  • 7.8.4 A&G Pharmaceutical Response to COVID-19 and Related Developments
• 7.9 Affymetrix Inc
  • 7.9.1 Affymetrix Inc Business Overview
  • 7.9.2 Affymetrix Inc Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
  • 7.9.3 Affymetrix Inc Non-Invasive Cancer Diagnostics Product Introduction
  • 7.9.4 Affymetrix Inc Response to COVID-19 and Related Developments
• 7.10 Precision Therapeutics
  • 7.10.1 Precision Therapeutics Business Overview
  • 7.10.2 Precision Therapeutics Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
  • 7.10.3 Precision Therapeutics Non-Invasive Cancer Diagnostics Product Introduction
  • 7.10.4 Precision Therapeutics Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US